RTC
ALNY icon

Riverview Trust Company’s Alnylam Pharmaceuticals ALNY Stock Holding History

Riverview Trust Company’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-78
Closed -$21.1K – 241
2025
Q1 		$21.1K Hold
78
– – 0.02% 411
2024
Q4 		$18.4K Buy
78
+75
+2,500% +$19.7K 0.02% 505
2024
Q3 		$825 Buy
+3
New +$781 ﹤0.01% 671
2024
Q2 		– Sell
-104
Closed -$15.5K – 627
2024
Q1 		$15.5K Buy
+104
New +$17.3K 0.01% 583
2023
Q3 		– Sell
-67
Closed -$12.7K – 678
2023
Q2 		$12.7K Buy
+67
New +$13.3K 0.01% 641
2022
Q2 		– Sell
-94
Closed -$15K – 711
2022
Q1 		$15K Buy
+94
New +$14.3K 0.01% 598

Other funds holding ALNY

Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.7T AUM 30.48% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
RP
Regeneron Pharmaceuticals Tarrytown, New York $47.9M AUM 29.29% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return